Burning Rock Biotech Limited's SEC filings document its status as a foreign private issuer with American depositary shares and its NGS-based precision oncology business. Form 6-K reports furnish quarterly and annual financial results, business updates for therapy selection, MRD, early detection and pharma services, and exhibits incorporated by reference into Form F-3 registration statements.
The company's disclosure record also includes annual Form 20-F reporting with audited consolidated financial statements. These filings address operating results, segment revenue, research and development spending, ADS-related matters, governance and risk factors for a China-based cancer diagnostics issuer.
Burning Rock Biotech reported much narrower losses for 2025 as efficiency improved. Full-year revenue reached RMB539.6 million, up 4.6% from 2024, while gross margin rose to 74.7% from 70.3% as cost of revenues fell 10.9%.
Operating expenses dropped sharply to RMB457.8 million from RMB720.0 million, helped by budget controls and headcount reductions, reducing net loss to RMB55.3 million from RMB346.6 million. In the fourth quarter, revenue was RMB126.3 million, gross margin climbed to 78.0%, and net loss shrank to RMB15.4 million from RMB81.3 million. Cash, cash equivalents and restricted cash totaled RMB481.1 million as of December 31, 2025.
Burning Rock Biotech Limited has furnished a Form 6-K as a foreign private issuer to provide a press release, filed as Exhibit 99.1. The company states that Exhibit 99.1, excluding the sections and table relating to non-GAAP measures, is incorporated by reference into its effective Form F-3 registration statement.